Carlos Cabrera1, Lei Chang1, Mars Stone2, Michael Busch3, David H Wilson4. 1. Quanterix Corporation, Lexington MA; 2. Blood Systems Research Institute, San Francisco, CA; 3. Blood Systems Research Institute, San Francisco, CA; University of California, San Francisco, San Francisco, CA. 4. Quanterix Corporation, Lexington MA; dwilson@quanterix.com.
Abstract
BACKGROUND: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital p24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. METHODS: We developed an investigational 69-min immunoassay for p24 capsid protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of p24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary p24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. RESULTS: Analytical sensitivity was 0.0025 ng/L p24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was <10% for samples as low as 0.09 ng/L. Clinical specificity was 95.1%. Sensitivity concordance vs NAT-VL on dilutions of preseroconversion samples and Group M viral isolates was 100%. CONCLUSIONS: The digital immunoassay exhibited >4000-fold greater sensitivity than contemporary immunoassays for p24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
BACKGROUND: Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report development and preliminary validation of a simple, low-cost, fully automated digital p24 antigen immunoassay with the sensitivity of quantitative NAT viral load (NAT-VL) methods for detection of acute HIV infection. METHODS: We developed an investigational 69-min immunoassay for p24 capsid protein for use on a novel digital analyzer on the basis of single-molecule-array technology. We evaluated the assay for sensitivity by dilution of standardized preparations of p24, cultured HIV, and preseroconversion samples. We characterized analytical performance and concordance with 2 NAT-VL methods and 2 contemporary p24 Ag/Ab combination immunoassays with dilutions of viral isolates and samples from the earliest stages of HIV infection. RESULTS: Analytical sensitivity was 0.0025 ng/L p24, equivalent to 60 HIV RNA copies/mL. The limit of quantification was 0.0076 ng/L, and imprecision across 10 runs was <10% for samples as low as 0.09 ng/L. Clinical specificity was 95.1%. Sensitivity concordance vs NAT-VL on dilutions of preseroconversion samples and Group M viral isolates was 100%. CONCLUSIONS: The digital immunoassay exhibited >4000-fold greater sensitivity than contemporary immunoassays for p24 and sensitivity equivalent to that of NAT methods for early detection of HIV. The data indicate that NAT-level sensitivity for acute HIV infection is possible with a simple, low-cost digital immunoassay.
Authors: Adrienne E Swanstrom; Alison Jacques; Gregory Q Del Prete; Paul Bieniasz; Theodora Hatziioannou; Robert Gorelick; Jeffrey D Lifson Journal: AIDS Res Hum Retroviruses Date: 2019-02-13 Impact factor: 2.205
Authors: Guoxin Wu; Michael Swanson; Aarthi Talla; Donald Graham; Julie Strizki; Daniel Gorman; Richard Jo Barnard; Wade Blair; Ole S Søgaard; Martin Tolstrup; Lars Østergaard; Thomas A Rasmussen; Rafick-Pierre Sekaly; Nancie M Archin; David M Margolis; Daria J Hazuda; Bonnie J Howell Journal: JCI Insight Date: 2017-08-17
Authors: Stephen W Wietgrefe; Lijie Duan; Jodi Anderson; Guillermo Marqués; Mark Sanders; Nathan W Cummins; Andrew D Badley; Curtis Dobrowolski; Jonathan Karn; Amélie Pagliuzza; Nicolas Chomont; Gérémy Sannier; Mathieu Dubé; Daniel E Kaufmann; Paul Zuck; Guoxin Wu; Bonnie J Howell; Cavan Reilly; Alon Herschhorn; Timothy W Schacker; Ashley T Haase Journal: J Virol Date: 2022-07-20 Impact factor: 6.549
Authors: Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque Journal: JCI Insight Date: 2018-10-04
Authors: David M Margolis; Nancie M Archin; Myron S Cohen; Joseph J Eron; Guido Ferrari; J Victor Garcia; Cynthia L Gay; Nilu Goonetilleke; Sarah B Joseph; Ronald Swanstrom; Anne-Marie W Turner; Angela Wahl Journal: Cell Date: 2020-03-26 Impact factor: 41.582
Authors: Adrienne E Swanstrom; Robert J Gorelick; Guoxin Wu; Bonnie Howell; Anitha Vijayagopalan; Rebecca Shoemaker; Kelli Oswald; Siddhartha A Datta; Brandon F Keele; Gregory Q Del Prete; Elena Chertova; Julian W Bess; Jeffrey D Lifson Journal: AIDS Res Hum Retroviruses Date: 2018-07-10 Impact factor: 2.205